1. Home
  2. MRCY vs MIRM Comparison

MRCY vs MIRM Comparison

Compare MRCY & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercury Systems Inc

MRCY

Mercury Systems Inc

HOLD

Current Price

$97.52

Market Cap

5.1B

Sector

N/A

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$97.06

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRCY
MIRM
Founded
1981
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
5.7B
IPO Year
1997
2019

Fundamental Metrics

Financial Performance
Metric
MRCY
MIRM
Price
$97.52
$97.06
Analyst Decision
Buy
Strong Buy
Analyst Count
8
13
Target Price
$80.00
$119.85
AVG Volume (30 Days)
495.0K
1.0M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
72.69
74.59
EPS
N/A
N/A
Revenue
$912,020,000.00
$19,138,000.00
Revenue This Year
$6.59
$26.22
Revenue Next Year
$9.56
$22.04
P/E Ratio
N/A
N/A
Revenue Growth
9.19
N/A
52 Week Low
$47.53
$43.40
52 Week High
$103.81
$114.99

Technical Indicators

Market Signals
Indicator
MRCY
MIRM
Relative Strength Index (RSI) 66.09 45.97
Support Level $72.03 $95.68
Resistance Level $103.81 $98.03
Average True Range (ATR) 3.87 5.94
MACD 0.65 -1.05
Stochastic Oscillator 72.08 15.08

Price Performance

Historical Comparison
MRCY
MIRM

About MRCY Mercury Systems Inc

Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: